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001 002
The Biology of Melanoma Micrometastases Genetic and Phenotypic Changes of Cancer Micrometastases
R.L. Barnhill K. Pantel
Pathology Services Inc, Cambridge, Massachusetts, U.S.A. Molecular Oncology, Department of Gynecology and Obstetrics, University Hospital Eppendorf,
The biology and significance of micrometastases remain poorly understood. Whether such deposits Hamburg, Germany. E-mail: Pantel@uke.uni-Hamburg.de
represent hypothetical ‘‘dormant’’ metastases or are simply the earliest metastases recognizable, or Using monoclonal antibodies to epithelial cytokeratins (CK) or tumor-associated cell membrane
both, has not been resolved. In attempting to answer the latter question among many others, we glycoproteins, individual carcinoma cells can be detected on cytologic preparations at frequencies
have carried out studies on the rates of proliferation, apoptosis, and microvessel counts in melanoma of 10–5–10–6. Prospective clinical studies have shown that the presence of these immunostained
micrometastases taken from sentinel lymph nodes as compared to conventional melanoma lymph cells in bone marrow and lymph nodes of patients without clinical or histopathological signs of
node macrometastases. We found that these micrometastases were not vascularized and had low metastases is prognostically relevant. In addition to immunocytochemistry, new molecular detection
(and comparable) rates of both proliferation and apoptosis, suggesting a steady-or dormant state. methods based on the amplification of a marker mRNA species by the polymerase chain reaction
On the other hand the macrometastases were fully vascularized and more proliferative, i.e., they technique have been developed. The current assays may be used to improve tumor staging with
had rates of proliferation that were both significantly higher compared to the micrometastases and potential consequences for adjuvant therapy. Another promising clinical application is monitoring
compared to the rate of apoptosis. How micrometastases develop is also poorly understood. Tumor the response of micrometastatic cells to adjuvant therapies, which, at present, can only be assessed
cells are thought to arrive in lymph nodes and other sites through the blood and lymphatic retrospectively after an extended period of clinical follow-up. Moreover, the screening methods
circulation and to extravasate. However, in addition to the latter explanation, another mechanism can be applied to detect tumor cells in the autologous transplant. The extremely low frequency
may be operable which we have proposed as extravascular migratory metastasis. In studies of metastatic of bone marrow tumor cells greatly hampers approaches to obtain more specific information on
melanoma we have identified melanoma cells positioned on the surface of endothelial cells both their biological properties. The available data indicate that these cells represent a selected population
by light and electron microscopy. We have also identified ultrastructurally the presence of an of cancer cells which, however, still express a considerable degree of heterogeneity with regard
amorphous matrix interposed between the latter two cell types that shows immunostaining for to chromosomal aberrrations and phenotypic properties. Prominent characteristics of bone marrow
laminin and recently the beta-2 chain of laminin. Thus we currently believe that the latter form tumor cells at the time of primary tumor diagnosis are the lack of both p53 mutations and
of ‘‘free’’ laminin may play a role in this other proposed mechanism of metastasis and thus the proliferation-associated marker proteins and the frequent overexpression of the erbB2 oncogene.
formation of micrometastases. Identification of the molecular determinants of micrometastasis may help to design new strategies
to detect and eliminate minimal residual cancer.
003 004
Quantifying Residual Disease Detection of Micrometastasis Through Tissue-Specific Gene Expression: The Promise and
U. Keilholz and N. Max the Problems
Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, R. Jung, W. Kru¨ger, K. Haack, C. Wagener, and M. Neumaier
Hindenburgdamm 30, 12200 Berlin, Germany Departments of Clinical Chemistry and Bone Marrow Transpl., Universita¨ts-Krankenhaus Eppen-
Quantification of tumor mRNA markers expressed by residual circulating tumor cells may be of dorf, Hamburg, Germany
prognostic value in a variety of neoplasms and disease stages. We therefore developed novel, real- The detection of micrometastasis holds great promise for an earlier staging of patients with
time nested PCR assays to quantify rare transcripts with the Light Cycler system. Quantification malignant diseases and may ultimately guide therapeutic decisions. So far, rtPCR amplification of
was demonstrated using tyrosinase mRNA, expressed by melanocytes and melanoma cells. 10 ml genes that the tumor expresses in a tissue-specific manner, is the method with the highest
EDTA blood from healthy volunteers were spiked with SkMel 28 melanoma cells (10–104). diagnostic sensitivity. It is well established that the identification of single tumor cells is feasible in
Following RNA extraction and cDNA synthesis, a nested PCR with specific primers was tissues and bodily fluids both in experimental and in clinical samples. However, at present it is
performed. Resonance energy transfer between flourescently labeled hybridization probes specific difficult to assign clinical significance to results obtained from such tests, primarily since diagnostic
for the amplified portion of the tyrosinase transcript allowed continuous monitoring of the second specificity is being disputed for a number of reasons both conceptionally and methodologically.
round of PCR. The number of preamplification cycles in the first round was varied between 20 For example, amplification of candidate mRNA targets is detectable in noncancer patients using
and 35. Quantitation of a house keeping gene or – more reliably – of an internal standard construct conditions that generally fail to generate such signals from healthy individuals. We have established
added to the blood sample, provides the sensitivity of the analysis on a per sample basis. Our that transcription of the tissue-specific genes can be affected by different means. Specifically, some
results show that nested PCR revealed quantitative data regardless of the number of cycles used target mRNA species are detectable in peripheral blood nuclear cells as low abundance constitutive-
in the first round. The range of real-time data can span 4 logs of target mRNA concentrations like expression, whereas others are induced through in vitro tissue culturing. In addition, mRNA
(1–103 tumor cells per ml of blood) and the x-intercepts of the log phases were always consistent expression may be distinctly upregulated by different cytokines/growth factors in vivo. Also,
with the amount of transcripts in the sample. These experiments indicate that nested PCR can background transcription of target mRNAs can occur in different lineages of peripheral blood
be quantitative and is a useful tool for the quantification of rare transcripts – a result with important cells. Finally, expression may be substantially different in tissues like peripheral blood, bone marrow
implications for the study of minimal residual disease. or lymph nodes. As a consequence, cancer patients may, in unrelated clinical situations, present
with different levels of background expression, making the diagnostic specificity of a test result
difficult to assess. To add to this complexity, an increasing body of literature is being generated
using various targets for a multitude of malignant diseases. Mostly, there is a great variety of
methods for sampling, specimen processing, nucleic acids recovery, test conditions and read-out
formats making comparability of data impossible. In summary, modalities of quantitative rtPCR
methods and standardisation issues should be discussed to address these questions.
005 006
Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining
Patients Immunomagnetic Cell Sorting and Immunocytochemical Staining
Ø. Fodstad, R. Faye, H. Høifødt, E. Skovlund, and S. Aamdal C. Siewert, M. Herber, N. Hunzelmann,* O. Fodstad,† S. Miltenyi, M. Assenmacher, and
The Norwegian Radium Hospital, Oslo, Norway J. Schmitz
Detection of tumor cells in blood and bone marrow of cancer patients might be useful in disease Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; *Department of Dermatology, University
staging and prognostication, and also provide means to increasing the understanding of the of Cologne, Cologne, Germany; †Department of Tumor Biology, The Norwegian Radium
metastatic process. In melanoma, most published studies have used RT-PCR methods, but very Hospital, Oslo, Norway
inconsistent results have been reported. We have developed a simple and highly sensitive Commonly used methods for detection of melanoma cells in blood, including RT-PCR and
immunomagnetic rosetting technique that allows for microscopical detection of down to 2–3 live immunocytochemistry, display only a limited sensitivity and specificity. Using these methods
melanoma cells in 23107 mononuclear cells within a time frame of 112–2 h. The method involves reliable detection of less than one melanoma cell per ml of blood is hardly possible. To obtain
the use of SAM 450 Dynabeads coated with the 9.2.27 anti-HMW antibody. Samples obtained greater sensitivities, so that a single melanoma cell in up to 25 ml of blood (53107 PBMC) can
from 103 patients, mainly with stage III or IV disease, have been examined. Micrometastatic cells be detected, we have developed a new assay for combined enrichment and immunocytochemical
were detected in 20 of 81 bone marrow and three of 103 peripheral blood samples. The results detection of disseminated melanoma cells from PBMC of patients with malignant melanomas.
were correlated to known clinical parameters of disease aggressiveness, and the presence of Melanoma cells are directly magnetically labeled using colloidal super-paramagnetic microparticles
micrometastases was found to be an independent and statistically significant prognostic indicator. (MACS MicroBeads, diameter approximately 60 nm) conjugated to an anti melanoma monoclonal
We have also developed a new immunofluorescence method, with antibody-coated latex antibody, 9.2.27, with no reactivity to normal cells in blood. Magnetically labeled melanoma cells
microspheres, for multiparameter characterization of membrane-expressed antigens on melanoma are enriched from PBMC by MACS and detected by a new approach for immunocytochemical
cells. The possibilities for using these methods in clinical and biological studies will be discussed. staining with monoclonal mouse anti melanoma antibodies (anti Melan A and HMB-45). The
efficiency of this assay was demonstrated in a model system in which 5–500 tumor cells from the
melanoma cell line SK-MEL-28 were seeded into PBMC samples from healthy donors containing
53107 leucocytes. Mean recovery of the seeded tumor cells was 47,4% 6 13,99% (n 5 15).
Applying the assay to 20–50 ml blood samples of patients with stage III–IV malignant melanomas
we were able to detect melanoma cells in two of eight patients (25%).
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Reverse Transcriptase Polymerase Chain Reaction (RTPCR) Detection of Melanoma Related Clinical Significance of Metastatic Melanoma Cells in Blood and Bone Marrow of Melanoma
Transcripts in the Peripheral Blood (PB) and Bone Marrow (BM) of Patients with Malignant Patients Using a Multimarker RT-PCR Assay
D.S.B. Hoon, P. Bostick, C. Kuo, K. Huynh, D.L. Morton, and S. O’DayMelanoma: What Have We Learned?
Departments of Molecular Oncology, Medical Oncology and Surgery Oncology, John WayneR. Ghossein and D. Coit
Cancer Institute, Santa Monica, California, U.S.A.Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.
Primary cutaneous melanoma can progress rapidly if not removed early, and spread to distal sitesThe detection of circulating tumor cells (CTC) and bone marrow micrometastases (BMM) by
via hematogenous routes. Detection of circulating tumor cells by RT-PCR is an approach toRT PCR may help predict recurrence and survival in MM. Since the original article of Smith
detect and monitor tumor progression. However, assay technology and marker development haset al (Lancet 338:1227, 1991), several groups have attempted the detection of CTC and BMM in
not been fully optimized. Our approach was to use a multiple marker assay to detect melanomaMM using RT PCR for melanocytic specific markers mainly tyrosinase mRNA. Most studies
cells in blood and bone marrow. Multiple markers used were of different biochemical pathwaysshow that tyrosinase is not present in the PB and BM of control individuals without MM. The
representing different melanoma-associated antigens. We observed significant correlation withPCR positivity rates in MM are extremely variable ranging from 0% to 100%. There was a
clinical stage and disease recurrence. Metastasis is one step of tumor progression as is spreading ofcorrelation between RT PCR and stage in some but not all the studies. These disparate findings
tumor cells in the blood. Detection of melanoma cells in blood and bone marrow can providecould in part be explained by differences in RNA extraction and blood separation techniques, to
valuable information as to events of disease progression that are occurring at the time of sampling.unrecognized contamination leading to false positive results or differences in patients selection.
These assays may be valuable as intermediate endpoints while monitoring therapeutic interventions.Despite these discrepancies, we and others have shown that RT PCR for tyrosinase mRNA in
Further correlations with clinicopathological factors and patient follow up will provide betterPB is able to predict overall survival (OS) and disease free survival (DFS) in a statistically significant
understanding of the significance of circulating melanoma cells in hematogenous compartments.manner. In AJCC stage II-IV patients who were rendered surgically free of disease, we found that
blood positivity was an independent predictor of OS and DFS. We also found that BM positivity
is an independent predictor of DFS in the same group of patients. RT PCR may help identify
subgroups of patients at high risk for early relapse for more aggressive adjuvant therapy. Large
prospective studies and interlaboratory quality assurance initiatives are necessary to confirm the
accuracy and prognostic value of these RT PCR assays.
009 010
Amplification of Tyrosinase and Melana Messenger RNA from the Peripheral Blood is Associated Detection of Tyrosinase Mrna in the Peripheral Blood of Melanoma Patients: Facts or Artefacts?
U. Reinhold, G. Rappl, S. Seiter, S. Ugurel, H. Abken,* and W. Tilgenwith Clinical Stage and Prognosis of Malignant Melanoma
Department of Dermatology, The Saarland University Hospital, Homburg/Saar; *Laboratory ofC. Garbe and B. Schittek
Tumorgenetics, Department of Internal Medicine, University of Cologne, GermanyDepartment of Dermatology, Tu¨bingen, Germany
Reverse transcription (RT) of the tyrosinase mRNA and specific cDNA amplification have beenWe analysed the influence of different parameters of sample processing on the sensitivity of the
reported to facilitate the early detection of circulating tumor cells in melanoma patients. Thetyrosinase RT-PCR using peripheral blood spiked with defined numbers of SKMEL28 melanoma
significance and practical value of this procedure for the diagnosis of tumor dissemination incells. Purification of the mononuclear cell fraction with a Ficoll gradient with a density of 1.077
melanoma patients, however, is still unclear. We analysed peripheral blood samples of melanomag per ml prior to RNA isolation resulted in the highest sensitivity with the detection of two
patients of different clinical stages for the presence of tyrosinase mRNA by RT-PCR. In additionSKMEL28 cells in 5 ml EDTA-blood. In addition, the RNA isolation method and the kind of
to a nested RT-PCR-based system we evaluated a new tyrosinase PCR-ELISA system forRT-enzyme used had a significant impact on the sensitivity and reproducibility of tyrosinase
sensitivity and specificity to detect circulating melanoma cells. Our results showed a high sensitivitydetection, whereas variations in the PCR conditions had only a minor influence. Furthermore,
and specificity for the tyrosinase PCR-ELISA system detecting one melanoma cell in 1 ml ofamplification of MelanA in addition to tyrosinase resulted in an enhanced sensitivity of melanoma
whole blood. No tyrosinase mRNA was detectable in blood samples of patients with primarycell detection, whereas gp100/pMel17 and MUC18 gene products were already detected in blood
melanoma and with regional lymph node metastases using different methods for detection. In afrom nonmelanoma patients. With the optimised protocol we investigated 340 blood samples
low number of patients (10–30%) with visceral metastases we found tyrosinase mRNA-positivefrom 225 melanoma patients for the presence of circulating tumour cells. Positive results for
results. Analyses of different blood samples taken in a 2-h intervall indicate that tumor cells onlytyrosinase or MelanA were obtained in 19% of stage I (n 5 74), 31% of stage II (n 5 45), 29%
transiently persist in the peripheral blood. Successful establishment of melanoma cell growth fromof stage III (n 5 48) and 52% of stage IV (n 5 58) patients. Amplification of MelanA in addition
tyrosinase mRNA-positive samples indicates that viable tumor cells exist in the peripheral bloodto tyrosinase resulted in an about 30% enhanced sensitivity of melanoma cell detection compared
of melanoma patients. Based on possible interlaboratory differences in the sensitivity and specificityto amplification of tyrosinase alone. The sensitivity could be further enhanced by analysis of at
of RT-PCR for tyrosinase we initiated a multicenter study in cooperation with seven laboratoriesleast two blood samples per patient and performing at least two PCR analyses per sample. Patients
testing blinded blood samples from melanoma patients with the new and standardized tyrosinasewith a positive PCR result showed already during a median follow-up time of 4 mo a 2.4-fold
RT-PCR-ELISA technique. Furthermore, our present results indicate a low amount of tyrosinase–increased relative risk for relapse than PCR negative patients. These data indicate that the detection
specific transcripts in a small subset of stage IV patients and confirm our assumption that theof circulating melanoma cells in peripheral blood by our optimised RT-PCR protocol using the
analysis of tyrosinase mRNA in peripheral blood samples is not helpful as a prognostic marker oramplification of tyrosinase and MelanA correlated with the clinical stage of disease and revealed
monitoring tool in melanoma patients.to be a prognostic factor for recurrence. In RT-PCR based diagnostics of melanoma patients
MelanA is a sensitive additional marker to tyrosinase for the detection of micrometastases.
011 012
Immunomagnetic Cell Sorting: Detection of 9.2.27 Positive Melanoma Cells in Peripheral Blood Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase Mrna in Bone Marrow and
A. Benez, U. Schiebel, and G. Fierlbeck Survival Time
Department of Dermatology, University of Tu¨bingen, Germany V. Waldmann, J. Wacker, M. Deichmann, A. Ja¨ckel, M. Bock, and H. Na¨her
We present a new, cellular approach to identify circulating melanoma cells in peripheral blood Department of Dermatology, University of Heidelberg, Germany
using immunomagnetic cell sorting. 205 blood samples from 155 melanoma patients and 30 Recent publications suggest that tyrosinase mRNA in blood as well as in bone marrow is detectable
samples from healthy persons and nonmelanoma patients were examined. After densitiy gradient only in a subgroup of patients with metastatic melanoma. We addressed the question, whether
centrifugation, the interphase was incubated with the murine mAb 9.2.27. The antibody recognizes patients with metastatic melanoma and with RT-PCR-detectable tyrosinase mRNA in blood or
a human melanoma-associated chondroitin sulfate proteoglycan, which is expressed on more than bone marrow have a different prognosis compared to tyrosinase mRNA-negative patients. Twenty
90% of all melanoma cell lines examined. 9.2.27 positive cells were labeled with magnetic melanoma patients with widespread clinical metastases were enrolled and the survival time after
microbeads and enriched by immunomagnetic cell sorting. Cells were stained using an alkaline first diagnosis of visceral metastases was correlated to tyrosinase mRNA presence in blood and
phosphatase-anti alkaline phosphatase assay and examined by light microscopy. In spiking bone marrow samples. Time of survival of eight patients with metastatic melanoma and detectable
experiments, melanoma cells, seeded at a concentration of one melanoma cell per ml whole blood, tyrosinase mRNA in either blood or bone marrow was not different from the prognosis of 12
could be detected reliably with the assay. Circulating melanoma cells were not found in 30 patients without detectable tyrosinase mRNA in either blood or bone marrow. Detection of
controls examined, nor were 9.2.27-positive cells found in 41 patients with primary malignant tyrosinase mRNA in blood or bone marrow samples of melanoma patients with advanced disease
melanoma. In patients with regional lymph node metastases, circulating 9.2.27-positive cells could seems to have no substantial relevance for survival time and outcome of disease. In this constellation,
be detected in three out of 29 patients (10%). All three positive patients presented with disseminated detection of tyrosinase mRNA by RT-PCR is not a valid tumor marker. Nevertheless, tyrosinase
metastases 4–8 wk after surgical removal of their metastases. In patients with disseminated disease, positivity in bone marrow in earlier tumor stages might indicate increased risk for the development
circulating melanoma cells were found in 13 out of 85 patients (15%) examined. The number of of distant metastases. This should be addressed for in further studies.
positive cells varied from 2 to 2364. This corresponds to about 0.5 to more than 400 melanoma
cells per ml whole blood. We conclude that immunomagnetic cell sorting is a sensitive and specific
approach to detect circulating melanoma cells in peripheral blood. Circulating melanoma cells
could be found in a number of patients with advanced disease. The method is not suitable for
early detection of metastases. However, a positive result may be indicative of bad prognosis. The
main advantage in comparison to PCR techniques is, that not only mRNA sequences but whole
melanoma cells may be identified. The method is a valuable tool to further investigate biological
characteristics of circulating melanoma cells.
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The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas Potential Value of FDG-PET for Initial Regional Staging in Melanoma
D. Bachter, C. Volkmar, C. Gerstel, H. Starz, H. Bu¨chels,* H. Vogt,† and B.R. Balda G.S. Mijnhout, P.J. Borgstein, O.S. Hoekstra, P.J. van Diest, R. Pijpers, S. Meijer, and G.J.J. Teule
Departments of Dermatology and *Allergology, Plastic Surgery and †Nuclear Medicine, Augs- Departments of Nuclear Medicine, Surgical Oncology and Pathology, University Hospital Vrije
burg, Germany Universiteit, Amsterdam, the Netherlands
At the beginning of a lymphogenous metastasizing process in malignant melanomas, the first Introduction: The sentinel node (SN) biopsy and FDG-PET are two new diagnostic methods in
tumor cells are found in the so-called sentinel node (sln), that is defined as the first tumor-draining staging of melanoma. SN biopsy proved to be a very sensitive and specific method for detection
lymph node. Its removal and histopathological examination enables us to discover metastases of of micrometastases in clinically tumour-negative regional lymph nodes. The detec-tion limit of
malignant melanomas a long time before their possibility of detection by all other methods, that PET for lymph node metastases is less clear. Rinne et al. (1998) reported a sensitivity and specificity
are known until now. Since the beginning of 1995 we have practiced more than 350 gamma- of 97% and 100%, respectively, and suggest that PET might compete with the SN biopsy in pts
probe guided sentinel lymphonodectomies (γ-slne) in patients without any clinical evidence of with Breslow . 1.5 mm. However, in a study by Crippa et al. (1998), PET detected only 27%
metastases after performing a lymphoscintigraphy. By this technique the detection and excision of of lymph node metastases , 10 mm. Wagner et al. (1998) compared SN biopsy and FDG-PET
the sln succeeded in nearly all cases. The slns were fixated in formalin, completely cut into 1 mm in the same patient group and detected only 17% of positive SNs with PET. Methods: We used
thin slices and stained, besides HE routine histology, with S-100 and HMB 45. In persons with our SN data to predict the potential value of PET for regional staging. Prospectively, 258
melanomas thinner than 0,75 mm we never found micrometastases. The slns were positive in consecutive pts with AJCC stage I and II cutaneous melanoma (Breslow 0.91–9.00 mm, mean
melanomas from 0,76 to 1,50 mm in about 8%, in those from 1,51 to 4,00 mm in about 18% 3.15) underwent SN mapping between September 1993 to January 1998. In pts with a positive
and in tumors thicker than 4 mm in about 42%. In primary melanomas with satellite or in-transit SN, the tumour area in the SN(s) was measured, using morphometry (video overlay system, Q-
metastases the slns contained in 75% metastases. Normally a radical lymph node dissection (rlnd) prodit). We predicted the value of PET, presuming detection limits of 3, 4 and 5 mm, respectively
follows, as it is considered as the necessary consequence of the detection of tumor cells. The (~7.07, 12.57 and 19.63 mm2).
lymph nodes of the rlnds contained in about 30% further metastases. The probability of the Results: In our cohort of 258 pts, lymphatic involvement was found in 53 pts (21%) by SN
involvement of lymph nodes besides the sln correlates with the extension of tumor cells in the procedure. The tumour areas of individual SNs ranged from 0.003 to 13.96 mm2 (median 0.42
sln. During our 4-y follow-up we watched only a single lymph node recurrence in a patient with mm2). Presuming a detection limit of 5 mm (~19.63 mm2), PET would have detected none of
a negative sln (false negative rate of about 0,4%). The development of systemic metastasis correlates, the metastases. Only two of 53 metastases (4%) were larger than the presumed detection limit of
besides the Breslow tumor thickness, very close to the extension of the involvement of the 4 mm (~12.57 mm2). If we presume a detection limit of 3 mm (~7.07 mm2), PET could have
melanoma metastasis in the sln. Summarizing it can be said, the γ-slne has revolutionized melanoma detected eight of 53 metastases (15%). Conclusion: This study corroborates and extends the
surgery. Based on our data it is absolutely necessary in the staging of malignant melanoma. To recently emerging evidence that PET should not have a role in routine nodal staging of clinically
our opinion, the existing staging systems, concerning the lymph node involvement, have to be negative basins in primary melanoma.
revised in consideration of the results of the slne.
015 016
Sentinel Node Biopsy in the Cutaneous Melanoma in the Masaryk Memorial Cancer Institute Has the Sentinel Node Procedure Changed the Pattern of Recurrence in Melanoma Patients?
V. Fait, V. Vagunda, V. Chrenko, Z. Pacovsky, D. Papirkova, and V. Sihotsky M.G. Statius Muller, P.A.M. van Leeuwen, P.J. Borgstein, and S. Meijer
Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czech Republic, CZ-656 53. E- Department of Surgical Oncology, Vrije Universiteit Academic Hospital, Amsterdam, the
mail: fait@mou.cz Netherlands
Sentinel node biopsy has been used in the Masaryk Memorial Cancer Institute since 1994. We Introduction: According to literature before the sentinel node (SN) era, the frequency of
are using the blue dye technique, as described by Morton. Before making lymphoscintigraphy in recurrences in melanoma patients is about 40%. Dependent on primary localisation and Breslow
1995 possible, we used it in extremities, then we widened it to all localities. We had only short thickness, the first site of recurrence is the regional lymph basin in 35–60%, in 20–30% the
possibility to try the hand held probe method. According to this short experience, we agree that locoregional area (in transit, local) and in 10–30% at a distance. About 65% of the relapses occurs
this modification is more quick and accurate, but due to the price of the probe stays for us impossible. within 3 y. The aim of this study is to determine the influence of the SN procedure in melanoma
The blue dye technique appeared to be much more difficult in the axillary region than in the patients on the first site of recurrence. Patients and methods: From 1993–1996 we performed a
groin. Although this method seems to be quite simple, experience is very important. Our SN procedure in 204 melanoma patients (86 man/118 women, age range 17–71 y). Breslow
successfulness in the first year was approximately 70%, it rose to the rate of approximately 98%. thickness varied from 0.5 to 9.0 mm. One day prior to surgery (dynamic) lymphoscintigraphy
From August 1994 to May 1999 220 patients with 222 melanomas were operated, 237 lymphatic was performed to establish lymphatic drainage patterns and to define the number of SN(s). The
regions were explored. Sentinel node was not identified in 26 patients (11.8%). From the 194 operation started with injecting blue dye intracutaneously on either side of the scar. The hand-
(89.2%) patients with identified sentinel node 38 had metastasis in this node and, with exception held probe and blue dye were used to define the SN. Excised nodes were examined by routine
of one, complete regional dissection was performed. In the sentinel node positive group 38 haematoxylin/eosin and immunohistochemical staining. If the SN contained metastatic tumour
(34.2%) developed relapse and five died. In the sentinel node negative group developed relapse cells, a regional lymphadenectomy was performed at a later date. Patients were followed up every
seven (4.5%) patients, no patient died till now. In the group of unidentified sentinel nodes relapse 3–6 mo. Results: The median follow up is 3 y. So far, 36 patients (18%) developed a relapse of
developed in seven (26.9%) and four patients died. the disease: distant: 14 (39%), locoregional (skin): 20 (55.5%), regional lymph node basin: 2 (5.5%)
The frequency of positive sentinel nodes rose with the thickness of the primary tumor. We found Forty patients (19.5%) had a positive SN, of whom 40% developed a relapse. 162 patients (79.5%)
no positive node in patients with melanomas thinner than 1 mm. The status of the sentinel node were SN negative and developed in 10% only a relapse (p , 0.0001, χ2 test). In two patients
appears as a most powerful prognostic factor in the intermediate thickness melanoma, whereas in (1%), both clinical disease free at the moment, the SN has not been identified during surgery.
the thick melanomas (more than 4 mm) are quite frequent relapses event with negative sentinel node. Mortality so far in the SN positive group is 22.5%, while in the SN negative group it is only 6%
We conclude, that sentinel node biopsy appears as a powerful tool for identifying minimal (p 5 0.002, χ2 test). The estimated 5 y survival for the total group is 83%; in SN positive patients
metastatic disease, especially in the intermediate thickness group, but stays a method, which needs 59% and 89% in patients with a negative SN (p , 0.0003, log rank test). The pattern of recurrence
training and careful follow up. Even more promising seems the hand held gamma probe didn’t differ in patients with a positive or negative SN (locoregional: 11 negative SN, nine positive
modification, more simple, more effective, but also extremely more expensive method. SN; distant: seven negative SN, seven positive SN). Conclusions: As expected, the SN procedure
changes the patterns of recurrence due to the infrequency of appearance of regional node metastases
after an SN biopsy. The lymph node status is still one of the most important prognostic parameters.
Patients with a positive SN do have an increased risk to develop locoregional and distant metastases
and therefore have an increased mortality. The percentage of patients who develop a recurrence
during follow up after an SN procedure, has been decreased up till now compared to similar data
from literature before the SN era. An explanation may be the surgical intervention of the early
regional lymph node (micro)metastases.
017 018
Detection of Regional Melanoma Metastases by Ultrasound B-Scan, Cytology or Tyrosinase RT- Sensitivity of Ultrasound B-Scan compared to Physical Examination in Follow-Up of Melan-
PCR of Fine Needle Aspirates oma Patients
T. Proebstle, M. Schwu¨rzer-Voit,* W. Sterry,* J. Knop, and C. Voit* C. Voit, J. Knop,* W. Sterry, and T. Proebstle*
Department of Dermatology University of Mainz and *Department of Dermatology of the Charite´, Department of Dermatology of the Charite´, Humboldt University, Berlin; *Department of
Humboldt University, Berlin, Germany Dermatology, University of Mainz, Germany
Background: Physical examination and ultrasound B-scan screening are important follow-up Background: Follow-up of melanoma patients is directed to detect metastatic disease as early as
procedures in melanoma patients with regional disease. However, they do not allow definite possible, however, the value of ultrasound B-scan (UBS) for routine follow-up in addition to
diagnosis of suspicious lesions. Fine needle aspiration cytology (FNAC) enhances the diagnostic physical examination (PE) is still under debate. Aim of our study was to compare the efficacy of
accuracy in such patients but, unfortunately, reaches its technical limits, particularly when very both methods and to evaluate, if early detection of metastases could improve disease free and
small or necrotic lesions are examined. Methods: We simultaneously evaluated the sensitivity of overall survival. Methods: Over a period of 4 y 819 melanoma patients were followed prospectively.
physical examination, ultrasound B-scan, FNAC and tyrosinase-RT-PCR of fine needle aspirates 3011 PEs with concomitant UBS of in-transit routes and regional lymph node basins were
(FNA-PCR). Results: With clinical follow-up in 69 melanoma patients 81 regional lymph nodes performed. Suspicious lesions were diagnosed by fine needle aspiration cytology and pathology.
were detected by ultrasound B-Scan examination, nine of whom appeared to be palpable. FNAC Results: 242 (90.6%) of 267 patients with melanoma recurrences during the study period were
was successful in all 81 lymph nodes, while FNA-PCR failed to obtain RNA at detectable levels first recognized by PE or UBS. The sensitivities of both methods differed significantly (p 5
in two lymph nodes of two patients. Of 79 lesions which have been completely evaluated by B- 0.001). Metastases were detected by PE in only 61 of 242 cases (25.2%, 95%CI: 19.9–31.2%)
Scan, FNAC and FNA-PCR, 44 proved to be melanoma metastases by histopathology, while the whereas UBS revealed 240 recurrences (99.2%, 95%CI: 97.3–99.6%). The specificity was 98.4%
remaining 35 lesions were finally classified as nonspecific lymph nodes. Of the 44 melanoma (95%CI: 97.8–98.8%) and 98.3% (95%CI: 97.7–98.7%), respectively. The negative predictive
metastases 80% (n 5 35) have been detected by B-Scan, 90% (n 5 39) by FNAC and 100% (n 5 values were 93.8% (95%CI: 92.8–94.6%) for PE and, most strikingly, 99.9% (95%CI: 99.6–100%)
44) by FNA-PCR (p , 0.05 vs. FNAC, p , 0.005 vs. B-Scan). In the subclass of lesions with for UBS. The positive predictive values were 57.5% (95%CI: 47.5–66.9%) for PE and 83.3%
diameters below 10 mm the sensitivities were 72% (n 5 13), 78% (n 5 14) and 100% (n 5 18), (95%CI: 78.5–87.4%) for UBS. Survival of 103 patients presenting with first nodal recurrence was
respectively. In 35 regional lymph nodes classified as benign lesions, FNAC was always negative followed and analyzed by multiple Cox regression. Overall survival was affected by the diameter
while FNA-PCR produced one positive result. Neither of these methods did produce false of the largest metastasis (p 5 0.001) and the number of metastatic lesions (p 5 0.012).
positive results in 15 control lymph nodes of control patients. Conclusion: Ultrasound B-scan is highly effective in early detection of regional melanoma
Conclusion: FNA-PCR might have superior sensitivity as compared to FNAC or ultrasound B- recurrence. Overall survival from first nodal recurrence was worse with increasing size and number
Scan, particularly in melanoma lesions with diameters below 10 mm. of metastatic lesions.
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S-100B is a Suitable Marker for Malignant Melanoma MIA, a Serological Marker of Malignant Melanoma
J.M.G. Bonfrer, H.M. de Feij-de Graaf, C.M. Korse, and O.E. Nieweg A.K. Bosserhoff, R. Hein,† D. Dreau,‡ W. Stolz,* M. Landthaler,* and R. Buettner
The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam, The Netherlands Institute of Pathologie, RWTH-Aachen, *Department of Dermatology, University of Regensburg,
Early diagnosis of malignant melanoma is of essential importance as depth of growth is related to †Department of Dermatology, TU Munich, Germany; ‡Department of General Surgery Research,
prognosis. The S-100 protein is a calciumbinding protein of 21 KDa which is present in high Charlotte, U.S.A.
concentration in cells of the central nervous system. The S-100 protein has been used in the panel MIA (Melanoma-inhibitory-activity) was originally identified as an 11-kDa protein secreted from
of antibodies used in cytological diagnosis of malignant melanoma. malignant melanoma cells. We have shown that MIA is strongly expressed in melanoma and
We studied the prognostic value of S-100B in serum of 251 patients with pathologically proven melanoma cell lines but not in melanocytes and normal skin and prooved that MIA mRNA
malignant melanoma. 143 were female and 108 males. expression correlates with progressive malignancy of melanocytic tumors.
A significant difference in S-100B concentrations was found between stage I, II, IIIA, IIIB and Measuring MIA in serum by a sensitive and quantitative ELISA and investigating the potential of
IV (p , 0.0001). MIA serum levels as a novel marker for malignant melanomas showed that MIA can be used to
S-100B is a major predictor of survival, independent of stage. In 30 patients the S-100B changes monitor therapy and follow-up. In detecting development of new metastasis or progression of
in serum concentration were in agreement with clinical observations. In 19 of 22 patients with disease MIA positivity was faster than routine diagnostic in 60%. We have further measured MIA
progression of disease changes of initial S-100B increases of more than 102 were found. In 15 of serum levels during therapy. Until today 90 patients have been followed in their diseases, each
22 patients the increases were over 25%. Results from one year experience in our institute will patient with at least six intervals of measurements. In all but four patients a strict correlation
be discussed. between MIA serum level and course of disease could be found. The MIA serum level dropped
when patients were in remission, while rising when progression of the malignant melanoma could
be seen. In conclusion, our data suggest that MIA represent a novel serum marker for detection
of both clinically apparent and nonapparent metastatic melanoma disease and for monitoring therapy.
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Multicenter Study on the Sensitivity of ‘‘Melanoma-Inhibiting Activity’’-(MIA-) and S-100B- S100β and MIA are not Superior to LDH in Discriminating Progressive from Nonprogressive
Protein as Valid Tumor Markers of Metastatic Melanoma in Serum AJCC Stage IV Melanoma Disease
A. Hauschild, J.M. Bonfrer,* P. Stieber,† E. Djureen-Martenson,‡ and L.-O. Hansson‡ M. Deichmann, A. Benner,* M. Bock, A. Ja¨ckel, K. Uhl, V. Waldmann, and H. Na¨her
Department of Dermatology, University of Kiel, Germany; *Department of Clinical Chemistry, Department of Dermatology (Director: Prof. Dr Detlef Petzoldt), University of Heidelberg, and
Netherlands Cancer Institute, Amsterdam; †University of Munich (LMU), Germany; ‡Karolinska *Central Unit of Biostatistics R0700, German Cancer Research Center, Heidelberg, Germany
Hospital, Stockholm, Sweden Purpose: Monitoring advanced malignant melanoma, serum levels of S100β and melanoma
Whereas use of tumor markers in solid tumors has found wide acception, in melanoma patients inhibiting activity (MIA) were assessed for the ability to discriminate progressive from nonprogress-
such markers have not been officially by recommended so far. Measurement of MIA (ELISA test ive disease. S100β and MIA were supposed to be superior to conventional parameters like lactate
system; Boehringer Mannheim, Penzberg, Germany) in serum was recently described as very dehydrogenase (LDH).
sensitive and specific in metastatic melanoma (100% sensitivity in stage III/IV). Using a Patients and Methods: Seventy-one patients with stage IV malignant melanoma according to the
luminoimmunometric assay to quantify protein S-100B in serum (Sangtec 100-LIAmat, Sangtec criteria of the American Joint Committee on Cancer (AJCC) were included in the study. Results
Medical, Bromma, Sweden) a first study reported a 80% sensitivity in stage IV-melanoma patients. of re-staging examinations were used as independent reference standard for diagnosing progressive
Conducting an international multiinstitutional study it was now found that MIA and S-100B disease, and S100β, MIA, LDH and erythrocyte sedimentation rate (ESR) were determined in
measurement could be considered as sufficiently valid. A total of 1135 melanomas from different venous blood just before. Sensitivities and specificities of the parameters were calculated by logistic
stages of disease, 65 healthy donors and 951 patients with various benign and malignant diseases regression analysis. Discrimination ability was assessed by Somers’ Dxy rank correlation and the
were examined to report on the sensitivity and specificity of MIA-and S-100B tests. area under the ROC curve (ROC-AUC).
95% of patients belonging to the control group demonstrated tumor marker serum concentrations Results: All tested serum parameters were significantly elevated in progressive disease. The highest
below 8.0 µg per liter (MIA) and 0.2 µg per liter (S-100B), respectively. With respect to the sensitivities according to the established thresholds were found for S100β and MIA with 91% and
mean serum levels no significant differences between control patients and postsurgical melanoma 88%, respectively. LDH had the highest specificity with 92%. ESR dropped out of analysis because
patients (stage I/II) could be obtained. In contrast, stage III/IV patients (metastatic disease) clearly of low specificity. Calculating Somers’ Dxy and ROC-AUC values, S100β, MIA and LDH show
showed higher mean serum concentrations of MIA and S-100B compared to controls. Regarding high discrimination ability. By multiple logistic regression, LDH was identified to be the only
the above mentioned cut-off values we were able to identify 80% of patients with metastatic statistically significant marker for progressive disease. S100β and MIA did not provide additional
melanoma on the basis of a blood test only. Follow-up and monitoring examinations in a limited significant information, resulting from their high correlation with LDH with respect to clinical
number of patients furthermore indicate that MIA-and S-100B-serum changes adequately reflect outcome.
disease progression or regression. Conclusion: Elevated serum levels of S100β, MIA and LDH indicate current disease progression
In conclusion, MIA and S-100B serum measurements represent a very useful method in in AJCC stage IV melanoma. Unexpectedly, LDH resulted as the most relevant overall parameter.
the detection, stratification and monitoring of metastatic melanoma, not however, of occult
micrometastasis in early stages of disease (I/II).
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S100 in Peripheral Blood of Human Melanoma Chick Embryo Xenotransplants Technical Aspects and Clinical Relevance of Molecular Tools in the Detection of Micrometastasis
P. Kaskel, K. Kunzi-Rapp, U. Leiter, R.U. Peter, and G. Kra¨hn M. von Knebel Doeberitz, J. Lacroix, M. Koch, A. Scho¨del, S. Weichert, and J. Weitz
Department of Dermatology, University of Ulm, D-89070 Ulm/Donau, Germany Division for Molecular Diagnostics & Therapy, Department of Surgery, University of Heidelberg,
The chorionallantois membrane (CAM) provides natural substrates for all kind of tumour cells. INF 110, D-69120 Heidelberg, Germany. E-mail:: mvkd@aol.com or knebel@med.uni-heidel-
Chick embryos are naturally immunodeficient hosts. As the CAM can accept inoculation of berg.de
various tumours, it has been used as an experimental model for studying tumour invasion and Solid tumors evolve from cells which have lost control functions safeguarding their genomic
metastasis. Two to three days after transplantation of xenogenic tissue, the grafts are nourished by integrity. Consequently, proliferating cells within a tumor differ slightly from generation to
the host blood supply, but graft–host-interaction remains unclear. S100 is a dimeric, acidic generation. This permits the continuous production of new and subsequent selection of the best
protein of 21 kDa with intracellular calcium-binding capacity. It is a routine marker in adapted cells, which retain this capacity of self evolution. Surgical resection of all these cells is
immunohistopathology for the diagnosis of malignant melanoma (MM). Recently, S100 protein only rarely achievable. Thus many tumor cells often remain and are spread to distant sites in the
has been described as a tumour marker in human peripheral blood for MM metastases. S100 organism before diagnosis and surgical resection. Few of them might later grow out to metastatic
positive lymph node MM metastases taken from three individuals with histopathologically lesion. Lack of diagnostic techniques to detect either preneoplastic lesions or single spread cancer
confirmed diagnosis of MM and elevated S100 levels in peripheral blood before surgery of lymph cells often causes delayed diagnosis when curative therapy is no longer achievable. Recent advances
node metastases were transplanted onto 20 eggs. The control collective comprised 10 eggs in characterizing the molecular basis of genomic instability, identifying specific gatekeeper mutations
inoculated by either connective tissue (negative controls), nontransplanted eggs (neg. contr.) or and their functional consequences in neoplastic cells now permits the development of new, highly
melanoma primary cell culture (positive contr.), and four eggs with completely devitalized xenograft sensitive tests to identify either preneoplastic lesions or rare spread cancer cells. These techniques
tissue. After 5 d, blood samples were taken from a larger vessel of the CAM before collecting the carry a tremendous potential for simple and cost effective cancer early detection and screening
xenografts. An immunoluminometric assay for the detection of S100 in peripheral blood (expected assays as well as for diagnostic applications to identify spread cancer cells. Thus, they most likely
value 0.02 µg per liter to 0.12 µg per liter) was performed in a blinded manner. All negative will soon guide indication for surgical and adjuvant therapy protocols. However, due to the
controls as well as samples deriving from completely devitalized xenograft tissue were S100 complexity of the assays and the great variety of technical aspects involved almost all diagnostic
negative while positive CAM controls showed highly elevated S100 levels of up to 1.19 µg per applications are not yet standardized. This poses significant problems for quality control and also
liter. Samples deriving from human MM metastasis CAM xenografts were positive in 80% with interlaboratory comparability of the results and underlines the urgent demand for well controlled
S100 levels up to .32 µg per liter. These results are in accordance to published data on S100 in collaborative efforts to evaluate indications and diagnostic standards for these assays. The theoretical
the peripheral blood of patients with advanced MM. The chick-embryo model system as an background, basic principals and some diagnostic applications of these new tests will be reviewed.
intermediate stage between isolated cells and animal experiments represents a link between in vivo
and in vitro systems and does not raise ethical or legal questions or violate animal protection laws.
Our data strongly support the concept of graft–host-interaction and validates clinical and
histopathological findings concerning adherence of the tumours and extravasation of human MM
cells. Based on these preliminary data S100 levels in the peripheral blood of this CAM xenograft
system could help to determine the effect of exogenous stimuli such as radiation and therapeutic
agents on metastasation of the xenografts.
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The Clinical Relevance of Molecular Staging for Melanoma Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes
S. Shivers, W. Li, A. Stall, M. Stafford, F. Haddad, J. Messina, L.F. Glass, and D. Reingten of Malignant Melanoma (MM) Patients
Cutaneous Oncology Program, H. Lee Moffitt Cancer Center & Research Institute at the G. Palmieri, M. Strazzullo, P.A. Ascierto, S.M. R. Satriano, G. Botti, A. Daponte, A. Cossu, A.
University of South Florida, Tampa, Florida, U.S.A. Lissia, N. Mozzillo, G. Castello, and the Melanoma Cooperative Group
The presence of metastatic disease in the regional nodal basin is the most important prognostic Institute of Molecular Genetics, Alghero; National Tumor Institute, Naples; University of
indicator for patients with malignant melanoma. The metastatic status of the sentinel lymph node Sassari; Italy
(SLN), defined as the first node in the basin to drain a primary tumor, has been shown to represent RT-PCR with multiple markers has been demonstrated to be highly sensitive in detecting
that of the whole basin. Since routine histologic examination of lymph nodes often underestimates metastatic cells in peripheral blood of MM patients, and the MM circulating cells to be significantly
the presence of micrometastatic disease, a more sensitive assay for detecting tumor cells is needed. correlated with disease stages (Palmieri et al.: J.C.O. 17:304–311, 1999). We further evaluated the
We have previously shown that a molecular assay based on the reverse transcriptase polymerase presence of specific PCR-positive mRNA markers in peripheral blood as well as in regional nodes
chain reaction (RT-PCR) was able to define a population of patients at higher risk for both as an expression of tumor progression. Peripheral blood samples from 295 MM patients with
recurrence and death, compared with routine H & E histology. Recently, we have compared either localized (#195) or metastatic (#100) disease were processed to obtain total cellular RNA.
‘‘molecular staging’’ of patients by RT-PCR with conventional s-100 and hmb-45 immunohisto- RT-PCR was performed using MUC18, tyrosinase, p97, and MelanA/MART1 as mRNA
chemistry (IHC) staining of the SLNs. In these studies, SLN specimens were bivalved and half of markers. PCR products were analyzed by gel-electrophoresis and Southern blot hybridization. In
each specimen was examined by routine histology, including both H & E and IHC. The other addition, paraffin-embedded samples of histologically proven tumor-negative lymph nodes from
half of each specimen was analyzed by a nested RT-PCR assay. H & E histology alone detected the subset of patients with localized disease were analyzed by RT-PCR, using radiolabelled primers
metastatic disease in 36 of 233 (16%) patients tested. Serial sectioning and ihc detected for tyrosinase and MelanA/MART1. Presence of mRNA markers was significantly correlated
micrometastatic disease in another 16 patients, thus increasing the proportion of patients with with tumor burden with a good correlation between risk of recurrence (evaluated in stage I-III
nodal disease to 22%. RT-PCR detected micrometastatic disease in 114 of 181 patients who were patients) and increasing number of PCR-positive markers (p 5 0.0002). For each patient, PCR
negative by conventional methods, further increasing the proportion of patients with evidence of results obtained at different times during follow-up are being analyzed and any variation in the
nodal disease to 70% overall. The clinical significance of this finding is currently uncertain. The number of PCR-positive markers is being correlated to the clinical status. Molecular screening of
value of additional therapy (including elective lymph node dissection and interferon therapy) for histological negative nodes for the presence of metastatic MM cells is under evaluation. Preliminary
patients who are positive only by the molecular method is being investigated by the multicenter assessment of a subset of patients with higher risk of recurrence needs longer follow-up in order
sunbelt melanoma trial. to define the role of RT-PCR in monitoring MM patients.
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Clinical Significance of Molecular Analysis of Sentinel Lymph Nodes in Primary Cutaneous Decrease in Circulating Melanoma Cells as an Early Marker of Therapy Effectiveness
J.-C. Bystryn, J. Albrecht, R. Oratz, R.L. Shapiro, D.L. Chen, M.C. Rivas, and A. ConradMelanoma
Departments of Dermatology, Medicine and Surgery, NYU School of Medicine, New York, NewH.-J. Blaheta, U. Ellwanger, B. Schittek, K. Sotlar,* H. Breuninger, and C. Garbe
York, and National Genetics Institute, Santa Monica, California, U.S.A.Departments of Dermatology and *Pathology, Eberhard-Karls-University, Tuebingen, Germany
As melanoma cells are present in the circulation of many patients with this cancer, decreases inRecently, histopathologic examination of sentinel lymph nodes (SLN) was shown to be the most
their number could provide an early indication of therapy effectiveness. To evaluate this possibility,important prognostic factor influencing disease-free survival in patients with primary cutaneous
we examined the effect of treatment with a melanoma vaccine on the number of melanoma cellsmelanoma. Using histopathologic techniques, however, the identification of isolated tumor cells
present in the circulation. PCR was used to detect melanoma cells that expressed the melanomaremains difficult. In order to improve the diagnostic accuracy of the SLN status the method of
associated antigens MART-1, MAGE-3, tyrosinase and/or gp100 in 70 pts with melanomareverse transcription-polymerase chain reaction (RT-PCR) for tyrosinase was used. The present
Melanoma cells that expressed one or more of these markers were detected in 23 (33%) pts. Thestudy investigates the clinical significance of RT-PCR analysis of SLNs in primary cutaneous
cells were present more often in advanced disease, i.e., in eight (50%) of 16 pts with stage IVmelanoma. In 116 patients with primary melanoma SLN biopsy was performed. SLNs were
compared to in 15 (28%) of 54 pts with stage IIB or III disease. We then measured circulatingbisected and analyzed by histopathology including immunohistochemistry and by tyrosinase RT-
melanoma cells in a subset of 43 of these pts who were treated with a polyvalent, shed antigen,PCR. Patients were followed-up for recurrent disease for 19 mo. A significantly higher sensitivity
melanoma vaccine. The vaccine contains multiple melanoma associated antigens including MART-of RT-PCR for tumor cell detection was demonstrated as compared with histopathology.
1, MAGE-3, tyrosinase and gp100. Immunizations were given intradermally q2–3 weeks34 andHistopathologic evaluation demonstrated nodal micrometastases in 15 patients (13%). In all of these
then monthly33. Prior to vaccine treatment, circulating melanoma cells were detected in 14SLNs, tyrosinase was detected. Thirty-six patients (31%) were found negative by histopathology but
(32%) pts. Following 3 and 5 mo of vaccine treatment, melanoma cells that expressed any of thesepositive by RT-PCR. Sixty-five patients (56%) were negative by both methods. The specificity
markers were present in only 10 (23%) and 3 (7%) of patients, respectively. Thus vaccine therapyof this technique was demonstrated by investigation of 68 lymph nodes of patients without
was associated with clearance of melanoma cells from the circulation in 78% of initially positivemelanoma that were negative for tyrosinase gene expression. Patients with melanoma cells detected
pts. As the number of these cells declined steadily with increasing length of therapy, it is unlikelyexclusively by RT-PCR had a significantly higher tumor thickness as compared to patients with
that this was due to a random change in their number. Rather it suggests that the decline was anegative RT-PCR results. Twenty-three (20%) out of the 116 patients developed melanoma
result of the therapy. These observations suggest that the presence of melanoma cells in therecurrences. Recurrences were observed in 10 patients (67%) who were positive by histopathology
circulation is related to the extent of the melanoma, and that their disappearance may provide anand by RT-PCR, in nine patients (25%) who were exclusively positive by RT-PCR, and in four
early marker of the efficacy of therapy. However, the practical utility of assaying circulating tumorpatients (6%) who were negative by both methods. The differences in recurrence rates were
cells as a guide to the effectiveness of therapy or of prognosis will need to be confirmed bystatistically significant (p , 0.01). In a multivariate regression analysis, the histological and RT-
correlations with clinical outcome.PCR status of the SLN were the only significant prognostic factors in predicting disease-free
survival. In this model, Breslow’s tumor thickness was no longer significant. This data is suggestive
that SLN biopsy and RT-PCR analysis are likely to become an important part of melanoma staging.
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Detection of Circulating Melanoma Cells in Stage II, III Melanoma – Powerful Prognostic Molecular Basis for the Implementation of Antigen-Specific Anti-Melanoma Vaccines
M.-B. Nielsen and F.M. MarincolaIndicators But Can We Use Them in Management?
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, U.S.A.B. Curry and P. Hersey
In recent years significant progress in the understanding of the immune biology of melanoma hasUniversity of Newcastle, Newcastle, NSW, Australia
evolved from the identification of Melanoma Antigens (MA) recognized by T cells. MA consistMelanoma is a potentially fatal skin cancer because of its propensity to metastasize to distant body
of intracellular proteins that are expressed on the surface of cancer cells in association with HLAsites. The risk of metastasis is related to primary tumor thickness and spread to lymph nodes (LN).
class I molecules and therefore are suitable targets for Cytotoxic T Cells (CTL). The peptideIn the present study we have investigated whether PCR assays for circulating melanoma cells or
sequences (epitopes) from MA responsible for recognition by CTL in association with differentS100b assays may assist in identifying patients with AJCC Stage I-III melanoma who will develop
HLA class I alleles have been also identified and have been used for the vaccination of patientsrecurrences from melanoma. Reverse PCR assays for MART-1 were found to complement similar
with advanced melanoma. Pilot clinical trials performed at the National Cancer Institute, Bethesda,assays for Tyrosinase in detection of CMC and were specific for melanoma, whereas similar assays
MD, have shown that epitope-specific vaccination is extremely effective in eliciting expansion offor gp100, p97 and Muc-18 were positive in blood from normal subsets. 276 patients were entered
melanoma-specific CTL reactivity in vivo. However, inexplicably, the amplification of immuneinto the study and 186 of these had been followed for 2 y. 73 patients had developed recurrences
responses caused by these vaccines is, in most cases, not sufficient to cause cancer regression.by this time. 50 of these (67%) were predicted to do so on the basis of the PCR tests. This
Thus, paradoxically, anticancer CTL can coexist with their target cells within the same organism.indicates that the tests would have failed to select 33% of the patients for some form of adjuvant
Among the multiple reasons why the immune competent host may tolerate melanoma is thetherapy. Addition of tests for S100b to the PCR assays increased the sensitivity to 81%. False
ability of cancer cells, characterized by progressively increased genetic instability, to rapidly adaptpositive rates cannot be assessed yet but may be approximately 15%. Despite these limitations, the
to immune pressure by loosing expression of target antigens, HLA alleles or in other ways favorablyPCR tests were powerful prognostic indicators and in multivariate analyses were more predictive
alter their phenotype. Thus, it is reasonable to suggest implementation of vaccination at an earlierof disease free survival (DFS) than tumor thickness or lymph node status. Patients with negative
stage in the natural history of the disease when the number of tumor cells is lower and theirtests by the PCR assays had a 3.2 fold longer DFS than those who were PCR positive. Patients
neoplastic dedifferentiation less advanced.who were negative in the LAI assays for S100b had a 2.7 fold longer DFS than those who were
negative. We also found that Tyrosinase positive, MART-1 negative tests were highly predictive
of distant metastases whereas when both tests were positive the recurrences were largely
locoregional. The significance of these results for clinical use of the tests is discussed.
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Dendritic Cells as Adjuvants for Immune-Mediated Resistance to Tumors A Novel Strategy in the Immunotherapy of Residual Melanoma: Chimeric Receptors Endow T
G. Schuler Cells with Tumor Specificity
Department of Dermatology, University of Erlangen-Nuremberg, Hartmannstr. 14, D-91052 H. Abken, U. Reinhold,* L. Liu, A. Hombach, C. Heuser, and S. Ferrone†
Erlangen, Germany Laboratory of Tumorgenetics, Department of Internal Medicine, University of Cologne, Germany;
Melanoma provides a compelling setting to pursue a current goal of cancer immunotherapy, i.e., *Department of Dermatology, The Saarland University, Homburg, Germany; †Department of
to generate strong and long-lasting tumor-specific T cell immunity particularly CD81 cytotoxic Immunology, Roswell Park Cancer Institute, Buffalo, New York, U.S.A.
T cells (CTLs). Vaccine therapy of melanoma is still at its beginning yet the identification of Melanoma cells frequently have abnormalities in antigen processing and loose human leukocyte
defined tumor antigens in conjunction with novel methods to monitor immune responses should antigen (HLA) class I expression allowing melanoma cells to escape from a being recognized by
allow the rational optimization of various immunization approaches. The injection of tumor- cytotoxic T cells. To target T lymphocytes to melanoma cells in a HLA class I independent
antigen carrying Dendritic Cells (DC), i.e., DC vaccination, is considered a particularly promising approach, we grafted T cells with a chimeric receptor that consists of an extracellular domain
strategy based on animal experiments. In the three pilot trials reported so far for humans, immature binding to a melanoma associated membrane antigen and an intracellular domain for cellular
DC have been employed. Scattered tumor responses are reported, but evidence for the induction activation. The binding domain is a single-chain antibody fragment (scFv) derived by phage
of tumor-specific CTL by established immunomonitoring methods has not been shown. We have display techniques from an antibody specific for high molecular weight-melanoma associated
recently used Mage-3 A1 or -A2 peptide-loaded, well defined mature DC generated from antigen, the intracellular domain is derived from the FcεRI receptor γ chain. Cytotoxic T cells
monocytes to vaccinate far-advanced stage IV melanoma patients. The use of the defined DC grafted with the chimeric receptor specifically bind to and lyse antigen-positive melanoma cells.
vaccine combined with detailed immunomonitoring for the first time provided the proof of This strategy combines the specificity of antibody-based and MHC-independent recognition with
principle that simple intracutaneous vaccination with mature DC expands tumor-specific T cells the potent cytolytic activity of T cells. The approach is designed to eliminate residual disseminated
even in far-advanced in melanoma patients. This methodology will allow to systematically intensify tumor cells by the power of cytolytic T cells that physiologically penetrate tissues and that are
DC vaccination further to reveal the presence of expanded populations of high-affinity effector specifically activated by the grafted receptor after binding to antigen.
cells. We are currently exploring whether efficacy can be increased at the level of the DC (by
CD40 ligation to improve their short life span in vivo), at the level of the T cell (by providing
melanoma-specific CD41 T cell help or IL-2), and by treating patients earlier in their disease course.
